A 51-year-old Calgary man who suffers debilitating cluster headaches has won a Federal Court battle forcing Health Canada to reconsider his bid for legal access to psilocybin to treat his extreme pain.
Ottawa Federal Court Judge Simon Fothergill, on May 24, granted an application for judicial review of Health Canada’s denial of Jody Lance’s bid for legal access to medical grade psilocybin — the active ingredient in hallucinogenic mushrooms — to manage pain associated with the headaches, which is so bad they have earned the nickname “suicide headaches.”
That decision — which also highlighted the need to consider a patient’s Charter rights — is being hailed by others fighting to access psilocybin for medical reasons.
Requests to access controlled substances in special medical circumstances are filed through Health Canada’s Special Access Program (SAP). In their July 12, 2023, SAP application Lance and his Calgary neurologist, William Jeptha Davenport, requested legal access psilocybin to help treat pain. Health Canada denied the request due to lack of research into the efficacy of the drug to treat cluster headaches.
The difficulty in patenting and mass producing bacteriaphages is the reason we don’t have them available in Western countries. But they are available in other places like Russia.
Bacteriaphages would be a huge boon to dealing with antibiotic resistant strains.
I thought bacteriophages were used against antibiotic-resistant infections, not cluster headaches.
I believe they were using it as an example of failure to corner the market, that is, in reply to the previous person’s comment and not directly to the main post.
Not talking about cluster headaches